[Pj-22] Japanese Poster Session 22 ALS 03

[Pj-22-4] Interim report of post-marketing surveillance of edaravone for ALS (SUNRISE Japan) 7th report

^○Kenta Yoshimura¹, Kaoru Ishizaki¹, Kengo Yoshida¹, Masao Matsuda¹, Yutaka Kawaguchi¹, Satoshi Yuki¹, Gen Sobue² (1.Mitsubishi Tanabe Pharma Corporation, Japan, 2.Nagoya university graduate school of mdicine / Aichi Medical University)